
Index

- Acetyl Cholinesterase (AChE) Inhibitors: 56, 62, 65, 71, 73–4, 113–14, 117
- Adverse Drug Reactions (ADRs): 6, 10, 11, 14–15, 18, 61, 68, 110, 178
- Alzheimer's Disease: 7
 autopsy confirmation: 39
 Computer Tomography (CT): 30, 41
 definition: 29
 diagnosis: 29, 40
 Magnetic Resonance Imaging (MRI): 41
- APOE4: 7, 175, 176
 clinical usefulness of test; 40, 41
 commercial test for: 35–7
 consensus view: 39, 43, 53, 65–9, 78, 85, 119–20
 differential diagnosis of Alzheimer's disease: 34, 36, 37, 38, 40, 41
 explaining risk of: 81–2, 124
 impact on families: 35, 40, 41, 67
 in clinical trials: 78–80, 83–4, 85, 86, 87, 119, 124, 126
 in prediction of Alzheimer's disease: 37, 38
 industry attitude: 86–90, 125
 insurance implications: 51–2
 need for further studies: 38, 42
 other forms of dementia: 79, 123–4
 overlap of use in research/clinical setting: 80–1, 82–3, 124–5
 practicality of test: see clinical usefulness
 public attitude: 85, 125
 risk of Alzheimer's disease: 30, 31–2, 34
 risk of heart disease: 32
 sensitivity and specificity of test: 41, 42–3
- And Tacrine link: 19–22, 23, 30, 44–5, 54, 57–9, 64, 65, 93, 130–1, 178
 professionals' views of: 59–60, 61, 62–4, 65, 93–4, 131
 size of clinical trials: 63
 clinical usefulness of: 61, 65, 69–70, 71, 112, 113
 ethics of: 65
 independent trial: 88–9, 126
 in different populations: 60
- Aricept: see Donepezil.
- Athena Neurosciences: 36, 37
- Beta-Amyloid: 33
- Breast Cancer: 22, 100, 135
 metastatic: 75, 99, 104, 117, 141, 154, 155, 162
 proactive patients: 163–5
 treatment: 100–2, 136
 'wars': 100
- Butyrylcholinesterase K: 72, 114, 115–16
- Chemotherapy: 101, 136
- Citicoline: 63
- Clinical 'Coal Face': 6, 7, 76, 109, 118, 151, 176, 178
- Clinical resistance: 7, 30, 43, 68, 71, 75, 92, 97, 107, 108, 111, 114, 129, 133, 134, 144, 147, 148, 176
 decision making framework: 73, 74
- Clinical Trials Directive: 90, 127–31
- Collins, Harry: 60, 91

- Consensus conferences on Genetic testing for Alzheimer's disease: 35, 45–53
- Alzheimer's Disease Genetics Consortium: 52
- American College of Medical Genetics' and the American Society of Human Genetics' Working Group on Apoe and Alzheimer Disease: 47
- American Geriatric Society: 51
- National Human Genome Research Institute and The National Institutes of Health: 48–9
- National Institute On Aging/Alzheimer's Association consensus group: 47–8
- National Institutes of Health Consensus Development Programme: 45
- Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging: 49
- Stanford Program in Genomics, Ethics and Society: 50, 52
- Consortium on Pharmacogenetics: 6, 68, 95, 111, 167
- Core set: 91, 92, 93, 95, 128, 130, 131
- CYP2D6: 10, 19
- Cytochrome P450: 12, 18
- DNA Arrays: 12
- Deficit model of public understanding of science: 96–7, 132–3, 180
- Department of Health (UK): 109, 150
- Deprenyl: 63
- Dobson, Frank: 87, 126
- Donepezil: 29, 62, 63
- European Medical Evaluation Agency (EMA): 68, 77, 111, 118
- Evidence-based medicine: 85, 125
- Exelon: see Rivastigmine
- Expectations: 7, 17–19, 23, 25, 26, 76, 118, 151, 176, 178, 180, 181
- sociology of: 15, 16, 17
- Experimenter's regress: 60, 61, 63
- Fluorescence In Situ Hybridisation (FISH) testing: 104, 107, 142, 145, 160
- Food and Drug Administration (FDA): 56, 73–4, 78–85, 99, 104, 117, 119, 134, 142
- Galantamine: 62, 63, 64, 65
- Genetics White Paper (UK): 2, 71, 89, 112, 126, 177
- Genentech: 23, 26, 79, 103, 104, 106, 115, 119, 139, 140, 142
- Genica Pharmaceuticals: 35, 36
- Genetic literacy: 95, 96, 97, 132, 133, 134
- GlaxoWellcome: 21
- GlaxoSmithKline: 68, 111
- Health Economics
- strong programme: 86, 126
- weak programme: 87–90, 94, 126, 127, 131
- HER2: 8, 102, 137–8, 176, 178
- as prognostic factor: 109, 149, 157, 176
- as genetic test: 159–60
- availability of testing: 107, 108, 109, 147, 148, 149
- disappointment at result: 162–3, 164
- ethics of sampling: 158, 160–1
- mechanics of testing: 153–6
- named prescriber system: 93, 130–1
- NHS funding of test: 93, 130
- overexpression: 24, 25, 73, 102, 103, 109, 117, 138, 140, 149
- role of histopathology service: 154–5, 179
- testing culture: 68, 71, 107–9, 111, 112, 113
- testing reference centres: 67–9, 71, 108, 110–12, 113, 114, 129, 149
- timing of test: 155–6
- quality assurance: 71, 113–14
- Herceptin: 7, 8, 99, 103, 134, 140–1, 175
- age in rationing of: 92, 128–9
- and cerebral metastases: 109, 150
- and long term survival: 109, 149
- as orphan drug: 78, 119–20
- as pharmacogenetics: 22–7
- clinical trials: 104, 142
- clinicians' attitude towards: 105, 109, 148, 150–1, 177
- compassionate use programmes: 72, 115–16
- development of: 99, 135
- ease of use: 107, 108, 147, 148
- efficacy: 104, 108, 109, 143, 148–9, 151
- ethics of Herceptin use: 166–73
- expanded access programme (UK): 71–5, 116–17
- financial constraints on use: 108, 148
- funding variations: 101, 102, 136, 166
- Herceptin as adjuvant (HERA) trial: 75, 117–19, 156, 163, 165, 172, 173
- industry's role: 151–2
- newspaper coverage: 99, 164
- rationing in use of: 92, 128

- risk of heart failure: 76, 104, 105–6, 118, 144
- side effects of: 104–6, 142
- use, prior to NICE decision: 107, 108, 136, 137, 147, 148
- Heterogeneous engineering: 16, 39, 106
- Human Genome Project: 3, 10, 11
- Hype: 15, 16, 17, 176, 181
- Industry: 1–2, 10–15, 21, 23, 35, 37, 62, 180–1
- Informed consent: 60, 80, 83–4, 153, 157, 158–9, 165, 169–71
- research vs. clinical context: 159, 171–3
- Immunohistochemistry (IHC) testing: 104, 107, 142, 144
- Lindpaintner, Klaus: 4, 23, 26
- Managed Care Organisations (MCOs): 12, 167
- Mastectomy: 100, 136
- Medical and Scientific Advisory Committee of Alzheimer's Disease International: 47
- Merck & Co.: 12
- Monoclonal Antibodies: 103, 140
- National Cancer Research Network (NCRN): 77, 118
- National External Quality Assessment Services (NEQAS): 72, 114
- National Health Services (NHS): 79–80, 124, 179
- differences compared to US funding: 169
- political context: 80–1, 124
- National Institute for Clinical Excellence (NICE): 8, 75, 109, 116, 117, 126, 150–1, 172
- 'NICE blight': 100, 101, 136
- appraisal committee: 103, 140
- appraisal process: 96–7, 132–3
- appraisal of HER2 test: 143
- approval of Herceptin: 69–70, 93–4, 110, 112, 131
- clinicians' expectations of Herceptin decision: 102, 137–8
- clinicians' views on NICE: 99, 103, 135, 140–1
- criticisms of: 85–6, 107, 125, 139, 145
- founding of: 82–3, 124–5
- health economists' views of: 89, 126
- impact of Herceptin decision on NHS: 104–6, 142, 149, 166, 167
- impact of Herceptin decision on NICE: 141–2
- influence on other health systems: 122
- narrative of evidence: 95, 103, 131, 132, 138, 139, 140
- narrative of politics: 95, 105–6, 131, 132, 139, 144
- need for extra evidence in appraisal: 97, 134
- Randomised Clinical Trial (RCT) data: 99, 134, 135, 143
- newspaper coverage: 100, 103, 135, 139
- political nature of NICE: 103, 140, 145
- Navelbine: see Vinorelbine
- Nuffield Council on Bioethics: 6, 166, 169
- Oestrogen receptor status: 101, 102, 108, 136, 148, 162
- 'One-size-fits-all': 10
- Ordinary technology: 7, 70, 102, 104, 110, 144, 162, 168, 175
- Personalised Medicine (see also pharmacogenetics): 9, 27, 39, 72, 75, 92, 102, 104, 114, 117–19, 143, 151, 176, 178
- definition: 4–5
- Pharmacologists: 21
- Pharmacogenetics: 151
- as heterogeneous technology: 6, 176, 178, 179
- attitude of industry: 71–5, 116–17
- citation of examples: 18, 20
- definition: 4–5
- economics: 79, 123–4, 144–5, 168, 179, 180
- ethical debates: 6, 67–9, 110–12
- ethnicity: 3
- history: 9–10
- professionals' view of: 60
- market segmentation: 87–90, 126
- public attitudes towards: 178
- regulation of: 179
- role of drug development costs: 13–14
- Pharmacogenomics: 4, 16, 179
- Politics: 3
- Poirier, Judes: 20, 35–7, 59, 64, 91
- & research group: 21, 44, 57, 62
- Primary Care Trusts (PCTs): 81–2, 124
- Promissory science: 17, 92, 128–9, 176
- Quality Adjusted Life Years (QALYs): 86–90, 125

- Rationing: 83–4, 90, 91, 124, 127–31
 age: 92, 129
 ‘postcode’: 84, 88–9, 100–2, 124, 126, 136
Reminyl: see Galantamine
Reverse salients: 30
Review articles: 18
Risk Evaluation and Education for Alzheimer’s
 disease (REVEAL) study: 85–6, 125
Rivastigmine: 29, 62, 63
Roche: 2, 8, 21, 26, 68, 72, 76, 96, 97, 102,
 103, 104, 107, 108, 110, 111, 114, 116,
 118, 132, 133, 134, 138, 139, 141, 143,
 149
Roses, Allen: 1, 2, 16, 31–2, 33, 34, 36, 37, 38,
 39, 46, 50, 52, 53, 68, 79, 94, 95, 119,
 122, 131
S12024: 63, 64, 72, 96, 116, 180
Slamon, Denis: 103, 138
SNP Consortium: 11
Sykes, Richard: 68, 111
Tacrine: 7, 56, 57, 61, 64
 and APOE: see APOE/Tacrine
Tamoxifen: 26, 101, 102, 108, 136, 148–9,
 162, 175, 180
Tau: 33
Technological visions: 17, 18
Trastuzumab: see Herceptin
Ullrich, Axel: 103, 139
Vinorelbine: 97, 99, 133, 134,
 151
Whitehouse, Peter: 46
Xanomeline: 63, 64